A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2023-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2 study (the second phase in testing a new drug) to see how useful an investigational drug called afatinib is in patients with advanced cancer with changes in the HER gene.

Afatinib is a drug that is approved by Health Canada for the treatment of advanced lung cancer with changes in the HER gene. Afatinib works by attaching to and blocking a protein called HER from working. HER is an important protein that contributes to the growth of cancer cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

NCT03810872

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

UNKNOWN PHASE2

Afatinib in NSCLC With HER2 Mutation

NCT02597946

Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE2

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

NCT02514174

Carcinoma, Non-Small-Cell Lung ErbB Receptors

COMPLETED PHASE4

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

NCT04439136

Advanced Lymphoma Advanced Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm +3 more

ACTIVE_NOT_RECRUITING PHASE2

Afatinib in NSCLC With HER2 Mutation

NCT02369484

NSCLC

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Afatinib

Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.

Group Type EXPERIMENTAL

Afatinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Afatinib

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GIOTRIF

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients may have had any number of treatment lines in the curative or metastatic setting for their solid tumors.
* Age 18 years or older.
* At least one measurable lesion
* In patients with previous treatment, evidence of progression of cancer, as per the opinion of the investigator must be present
* Eastern Cooperative Oncology Group (ECOG) performance status ≤1
* Adequate organ function
* Willingness to undergo fresh tumor biopsy at certain timepoints
* Recovered from any previous therapy related side effects
* Able to provide written consent

Exclusion Criteria

* Chemotherapy, biological therapy or investigational agents within 3 weeks prior to the start of study treatment.
* Hormonal treatment within 3 weeks prior to start of study treatment.
* Radiotherapy within 3 weeks prior to randomization with exceptions
* Major surgery within 3 weeks before starting study treatment or scheduled for surgery during the projected course of the study
* Known exposure to any epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2, HER3 or pan-HER inhibitors, such as, but not limited to afatinib or dacomitinib.
* Patients with inability to swallow whole tablets for afatinib are allowed on the study, but diluted tablets must be taken orally.
* Presence of malabsorption problems including, but not exclusively limited to chronic diarrhea and uncontrolled inflammatory bowel disease.
* History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to study entry
* Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 28 days after treatment has ended.
* Female patients of childbearing potential who are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by the study.
* Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the study drug
* Previous or concomitant malignancies at other sites, with exceptions
* Requiring treatment with any of the prohibited concomitant medications
* Known pre-existing interstitial lung disease
* Any history or presence of poorly controlled gastrointestinal disorders.
* Known active hepatitis B, active hepatitis C infection and/or known HIV carrier.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No